Facebook
Twitter
LinkedIn
Forward2022-2023 Monthly Oncology Tumor Boards: A Multidisciplinary Approach to Individualized Patient Care
The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) are a set of step-by step evidence-based, consensus-driven recommendations to ensure that patients receive preventive, diagnostic, treatment, and supportive services that are most likely to lead to optimal outcomes.
The NCCN Guidelines provide recommendations for appropriate care for about 95% of patients; however, individual patient circumstances must be considered when applying these recommendations. In all cases, clinicians need to consider the current clinical status of the patient, including general health, disease specifics, concomitant conditions, current and previous therapies, and the patient’s preferences when applying the guidelines to ensure optimal care for the individual. The multidisciplinary team discusses how to best apply appropriate standard of care, including identifying circumstances where appropriate management requires adapting the NCCN Guidelines to the needs of the individual.
This activity series will discuss the specific recommendations in the NCCN Guidelines as well as unique patient circumstances that impact how the guidelines might be best applied.
Target Audience
This educational program is designed to meet the educational needs of physicians/oncologists, nurse practitioners, nurses, physician assistants, pharmacists, and other health care professionals who manage patients with cancer.
Learning Objectives
The goal of this project is to ensure that members of the interprofessional oncology care team, including physicians, nurses, pharmacists and other relevant health care professionals, have the knowledge and skills necessary to:
- Apply the current standards of oncology care and NCCN Clinical Practice Guidelines in Oncology to optimize the management of patients with various cancer types.
- Review new, emerging, and novel therapeutic agents and treatment strategies and incorporate these into the management of patients with cancer.
- Communicate the importance of a multidisciplinary approach and improve the collaborative performance of the interprofessional oncology care team in the management of patients with cancer.
All live webinars in this series have been completed. The 2023-2024 series will be starting in June. More details coming soon!
ALL WEBINAR TIMES ARE POSTED AS EASTERN DAYLIGHT TIME (EDT) (UTC/GMT -4:00) OR EASTERN STANDARD TIME (EST) (UTC/GMT -5:00).
Access to participate in selected sessions is through the NCCN WebEx Site on the day of each scheduled program.
The most recent recorded webcasts from this series are listed below. Recordings from the previous NCCN Monthly Oncology Tumor Board Series can be found here.
- Management of Well-Differentiated Grade 3 Neuroendocrine Tumors (presented on June 23, 2022, by Jonathan R. Strosberg, MD; Ghassan El-Haddad, MD; and Taymeyah Al-Toubah, MPH, Moffitt Cancer Center)
- Management of Non-Metastatic Prostate Cancer (presented on July 6, 2022, by Edward Schaeffer, MD, PhD; Ashley E. Ross, MD, PhD; and Sean Sachdev, MD, Robert H. Lurie Comprehensive Cancer Center of Northwestern University)
- Updates in the Treatment of Nasopharyngeal Carcinoma (presented on August 29, 2022, by Jason W. Chan, MD; Hyunseok Kang, MD, MPH; Christine Kim, NP, MSN, UCSF Helen Diller Family Comprehensive Cancer Center)
- Treatment of Patients with Bladder and Upper Tract Urothelial Cancer (presented September 29, 2022, by Jean Hoffman-Censits, MD; Max Kates, MD; Steven Rowe, MD, PhD, The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins)
- Treatment of Patients with Kidney Cancer (presented October 25, 2022, by Eric Jonasch, MD; Surena F. Matin, MD; Chad Tang, MD, The University of Texas MD Anderson Cancer Center)
- Esophageal and Esophagogastric Junction Cancers: Postoperative Therapy in Patients with Residual Disease (presented November 9, 2022, by Sunnie Kim, MD; Jeffrey Olsen, MD, University of Colorado Cancer Center)
- Management of Early Stage Breast Cancer (presented December 14, 2022, by Rebecca Aft, MD, PhD; Nusayba Bagegni, MD; Joanna Yang, MD, MPH, Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine)
- Management of Patients with Multiple Myeloma (presented February 10, 2023, by Michaela Liedtke, MD, and Surbhi Sidana, MD, Stanford Cancer Institute)
- Use of Checkpoint Inhibitors for Treatment of Metastatic Colorectal Cancer (presented February 17, 2023, by Michael Overman, MD; Kanwal P.S. Raghav, MD, MBBS; Victoria Serpas Higbie, MD, The University of Texas MD Anderson Cancer Center)
- Uveal Melanoma: Treatment of Metastatic Disease (presented on April 10, 2023, by Miguel A. Materin, MD, Duke Cancer Institute; Harriet Kluger, MD, and Mario Sznol, MD, Yale Cancer Center/Smilow Cancer Hospital)
- Management of Relapsed/Refractory Mantle Cell Lymphoma (presented on April 18, 2023, by Julie E. Chang, MD; Priyanka Pophali, MD; and David T. Yang, MD, University of Wisconsin Carbone Cancer Center)
- Adjuvant Therapy for Patients with Resectable Early-Stage and Locally Advanced Non-Small Cell Lung Cancer (presented on May 16, 2023, by Malcolm DeCamp, MD; Toby Campbell, MD, MS; and Andrew Baschnagel, MD, University of Wisconsin Carbone Cancer Center)
NCCN Medical Education Disclosure Policy
It is the policy of NCCN that all planners, faculty, moderators, authors, reviewers and anyone involved in the planning and delivery of NCCN continuing education activities are expected to disclose ALL financial relationships they have had in the past 24 months with ineligible companies. The ACCME Standards for Integrity and Independence require that individuals who refuse to provide this information will be disqualified from involvement in the planning and implementation of accredited continuing education presented by NCCN. NCCN identifies, mitigates and discloses to learners all relevant financial relationships.
In addition, all content has been reviewed to ensure education promotes safe, effective patient care and does not promote the products or services of an ineligible company. Content, including any presentation of therapeutic options, is fair, balanced, evidence-based, scientifically accurate, and free of commercial bias and marketing.
Definitions
Ineligible Company: An ineligible company is any entity whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.
Relevant Financial Relationships: Financial relationships of any dollar amount occurring within the past 24 months are defined as relevant if the educational content an individual can control is related to the business lines or products of an ineligible company. There is no minimum financial threshold. We ask for disclosure of ALL financial relationships with ineligible companies, regardless of the amount and regardless of the potential relevance of each relationship to the education.
Faculty Disclaimers
All faculty for this continuing education activity are competent in the subject matter and qualified by experience, training, and/or preparation for the tasks and methods of delivery.
Faculty presentations may include discussion of off-label use. Faculty will disclose that the use in question is not currently approved by the FDA per the product labeling or marketing.
Full disclosure of faculty relationships will be made prior to the activity.
This program has been approved for AMA PRA Category 1 Credit™ for physicians and will award contact hours for nurses, pharmacists, case managers, and other health care professionals. Complete accreditation information is provided before each individual educational activity.
Price
NCCN Non-Discrimination/Harassment Policy – Affiliated Persons and Volunteers
NCCN is committed to providing workplaces and events that are free from discrimination or harassment of any kind for all participants, and has a zero-tolerance policy for any such conduct. NCCN requires individuals participating on NCCN Guidelines Panels, standing and ad hoc committees, meetings and seminars, or other NCCN-affiliated activities and events to adhere to this policy.
To access this policy including reporting procedures, please visit NCCN.org/non-discrimination.
Required Hardware/software
To complete this activity, users will need:
- A device with an Internet connection and sound playback capability
- One of the two latest versions of Google Chrome, Mozilla Firefox, or Safari
- Internet Explorer is no longer supported
- Adobe Reader or other PDF reader software for certificate viewing/printing